Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 6538 - 6556 |
| Number of pages | 19 |
| Journal | International Journal of Production Research |
| Volume | 52 |
| Issue number | 21 |
| DOIs | |
| Publication status | Published - 2014 |
Cite this
}
Innovative manufacturing in Australia's emerging regenerative medicine industry: centralised factories to decentralised facilities. / Teng, Chih Wei; O'Neill, Peter Joseph; Foley, Lucy.
In: International Journal of Production Research, Vol. 52, No. 21, 2014, p. 6538 - 6556.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Innovative manufacturing in Australia's emerging regenerative medicine industry: centralised factories to decentralised facilities
AU - Teng, Chih Wei
AU - O'Neill, Peter Joseph
AU - Foley, Lucy
PY - 2014
Y1 - 2014
N2 - Regenerative medicine therapies are showing great clinical promise in providing cures to life-threatening diseases such as cancer and diabetes. However, little emphasis has been placed on the industrialisation of these therapies for commercial purposes. The inability to scale production up and out to meet pending demand is of increasing concern to both regulators and funding agencies. Using an open innovation theoretic lens, this paper explores the importance of involving commercial partners within the lengthy research and development phases. We adopt a case study method to show that laboratory processes that incorporate innovative manufacturing techniques produce significant reduction in cost of quality (errors) and improved scalability, while satisfying regulatory requirements. We demonstrate that this approach enables faster industrialisation, and improves the funding efficiency of clinical trial outcomes in terms of quality, cost and commercial success of therapies.
AB - Regenerative medicine therapies are showing great clinical promise in providing cures to life-threatening diseases such as cancer and diabetes. However, little emphasis has been placed on the industrialisation of these therapies for commercial purposes. The inability to scale production up and out to meet pending demand is of increasing concern to both regulators and funding agencies. Using an open innovation theoretic lens, this paper explores the importance of involving commercial partners within the lengthy research and development phases. We adopt a case study method to show that laboratory processes that incorporate innovative manufacturing techniques produce significant reduction in cost of quality (errors) and improved scalability, while satisfying regulatory requirements. We demonstrate that this approach enables faster industrialisation, and improves the funding efficiency of clinical trial outcomes in terms of quality, cost and commercial success of therapies.
U2 - 10.1080/00207543.2014.962115
DO - 10.1080/00207543.2014.962115
M3 - Article
VL - 52
SP - 6538
EP - 6556
JO - International Journal of Production Research
JF - International Journal of Production Research
SN - 0020-7543
IS - 21
ER -